Abstract
Alzheimer disease (AD) is an age-related neurodegenerative disorder characterized by the presence of senile plaques, neurofibrillary tangles and neuronal loss. Amyloid-β protein (Aβ) deposition plays a critical role in the development of AD. It is now generally accepted that massive neuronal death due to apoptosis is a common characteristic in the brains of patients suffering from neurodegenerative diseases, and apoptotic cell death has been found in neurons and glial cells in AD. Melatonin is a secretory product of the pineal gland; melatonin is a potent antioxidant and free radical scavenger and may play an important role in aging and AD. Melatonin decreases during aging and patients with AD have a more profound reduction of this indoleamine. Additionally, the antioxidant properties, the anti-amyloidogenic properties and anti-apoptotic properties of melatonin in AD models have been studied. In this article, we review the antiamyloidogenic and anti-apoptotic role of melatonin in AD.
Keywords: Alzheimer disease, neurodegeneration, neuroprotection, melatonin, amyloid beta-protein, amyloid precursor protein, apoptosis, mitochondria
Current Neuropharmacology
Title: Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease
Volume: 8 Issue: 3
Author(s): Hongwen He, Weiguo Dong and Fang Huang
Affiliation:
Keywords: Alzheimer disease, neurodegeneration, neuroprotection, melatonin, amyloid beta-protein, amyloid precursor protein, apoptosis, mitochondria
Abstract: Alzheimer disease (AD) is an age-related neurodegenerative disorder characterized by the presence of senile plaques, neurofibrillary tangles and neuronal loss. Amyloid-β protein (Aβ) deposition plays a critical role in the development of AD. It is now generally accepted that massive neuronal death due to apoptosis is a common characteristic in the brains of patients suffering from neurodegenerative diseases, and apoptotic cell death has been found in neurons and glial cells in AD. Melatonin is a secretory product of the pineal gland; melatonin is a potent antioxidant and free radical scavenger and may play an important role in aging and AD. Melatonin decreases during aging and patients with AD have a more profound reduction of this indoleamine. Additionally, the antioxidant properties, the anti-amyloidogenic properties and anti-apoptotic properties of melatonin in AD models have been studied. In this article, we review the antiamyloidogenic and anti-apoptotic role of melatonin in AD.
Export Options
About this article
Cite this article as:
He Hongwen, Dong Weiguo and Huang Fang, Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease, Current Neuropharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157015910792246137
DOI https://dx.doi.org/10.2174/157015910792246137 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Progress in Multiple Sclerosis Genetics
Current Genomics Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice
Current Alzheimer Research Microglia Phenotype Diversity
CNS & Neurological Disorders - Drug Targets Role of Glycosphingolipids and Therapeutic Perspectives on Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design Can Environmentally Relevant Levels of Aluminium Promote the Onset and Progression of Neurodegenerative Diseases?
Current Inorganic Chemistry (Discontinued) Pharmacological Therapy of Parkinson’s Disease: Current Options and New Avenues
Recent Patents on CNS Drug Discovery (Discontinued) Polyphenols Beyond Barriers: A Glimpse into the Brain
Current Neuropharmacology Symmetry-Based Self-Assembled Nanotubes Constructed Using Native Protein Structures: The Key Role of Flexible Linkers
Protein & Peptide Letters Ether Glycerophospholipids and Their Potential as Therapeutic Agents
Current Organic Chemistry Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer’s Disease: A Translational Overview
Current Pharmaceutical Design Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy
Current Pharmaceutical Design Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Topical Discoveries on Multi-Target Approach to Manage Alzheimer’s Disease
Current Drug Metabolism Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Amyotrophic Lateral Sclerosis: A Genetic Point of View
Current Molecular Medicine Excitotoxicity as a Target Against Neurodegenerative Processes
Current Pharmaceutical Design New Anti-Alzheimer Drugs from Biodiversity: The Role of the Natural Acetylcholinesterase Inhibitors
Mini-Reviews in Medicinal Chemistry Transendothelial Migration of Monocytes: The Underlying Molecular Mechanisms and Consequences of HIV-1 Infection
Current HIV Research